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Strengths and limitations of this study
 ► This systematic review will include both studies of 
high healthcare use and/or high healthcare costs.
 ► It will include studies undertaken in general physical 
healthcare settings—primary, secondary care and 
emergency departments.
 ► It will focus on studies that have specifically record-
ed the presence of depression and/or anxiety in the 
high cost/high use population studied, using stan-
dardised questionnaires or clinical interviews lead-
ing to a clinical diagnosis.
 ► We will provide a narrative summary of findings with 
sources of variation and bias based on a compre-
hensive data extraction framework, with relevant 
subgroup analyses and interpretations based on: 
country, type of healthcare system, location of study 
(primary, secondary care, emergency department or 
total healthcare) and way of recording depression/
anxiety.
 ► A meta-analysis may not be feasible given a likely 
high level of heterogeneity in outcome definitions 
and measurements.
ABSTRACT
Introduction In all healthcare settings, a small proportion 
of patients account for a large level of healthcare use and 
associated high healthcare costs. Depression and anxiety 
are common co-morbidities in patients who are high users 
of care. The aims of this systematic review are to: (1) 
estimate the prevalence of anxiety/depression in adults 
who are high users of general physical healthcare services 
and/or who accrue high healthcare costs (2) estimate the 
magnitude of healthcare use associated with the presence 
of anxiety/depression.
Methods and analysis This review will include any 
studies where patients are high users of primary, 
secondary or emergency healthcare services and/or 
accrue high healthcare costs. This is the first systematic 
review to focus on patients who are over the age of 
18, whose degree of anxiety/depression has been 
evaluated with a standardised questionnaire or by a 
clinical interview generating a diagnosis according to 
international diagnostic criteria. The review will include 
eligible studies indexed in Medline, PsychINFO, Embase, 
Cumulative Index to Nursing and Allied Health Literature, 
Prospective Register of Systematic Reviews, Cochrane 
Library from inception to 1 April 2019. We will estimate the 
prevalence of anxiety/depression in these populations and 
the magnitude of use associated with anxiety/depression 
across various general physical healthcare settings. We 
will provide a narrative description of findings and factors 
that may influence them. A meta-analysis may be pursued 
if the degree of heterogeneity across studies is acceptable.
Ethics and dissemination This systematic review will 
use data from existing studies, hence no ethical approvals 
are required. Findings will be disseminated in a peer-
reviewed publication and at relevant academic meetings.
PROSPERO registration number PROSPERO 
CRD42018102628.
InTROduCTIOn
The cost of healthcare in developed coun-
tries has continued to grow over the recent 
years, and the current projected trajectories 
of growth are unsustainable.1 This situation 
is particularly severe in the USA, where the 
cost of healthcare is nearly twice that of most 
other developed countries.1 2 Across health-
care systems, a small proportion of patients 
account for a large proportion of healthcare 
use and cost.3 These findings have consis-
tently emerged from studies of general prac-
tice (GP) attendances,4 inpatient length 
of stay,5 6 outpatient appointments7 and 
emergency department (ED) services.8–10 
In primary care, approximately 10% of 
‘frequent attenders’ account for up to 39% 
of all consultations.11 In the USA, approxi-
mately 5% of patients account for about 50% 
of all US healthcare spending.12
It has been suggested that approximately 
50% of high users of healthcare in primary 
and secondary care have significant mental 
health problems, either alone or, in addi-
tion to physical health needs, and have been 
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termed ‘distressed high users’.13 High use of healthcare 
services has been associated with a variety of mental health 
problems including multiple psychiatric diagnoses,14 15 
long histories of psychological ill health,16 17 history of 
childhood abuse or neglect18 or addictions.19
A recent systematic review of the general characteristics 
of high-cost patients found a high prevalence of multiple 
chronic conditions among this patient population.20 
Mental health problems were also common but varied 
according to the healthcare system. In US Medicaid, the 
prevalence of mental illness ranged from 30% to 75%, 
whereas in US Medicare, the prevalence was between 
10% and 25%. One of the main findings of the review 
was that high-cost patients were more likely to have a 
mental health disorder. There were, however, no details 
as to the nature of mental health problems experienced 
by these high-cost patients, as data were grouped under a 
broad category of mental and behavioural disorders. This 
review will focus on patients with depression and anxiety 
disorders, as they are the most common form of mental 
disorder. We will focus on studies where depression and 
anxiety are identified through standardised question-
naires or by clinical interviews leading to a clinical diag-
nosis. Our review will provide information about the 
prevalence of depression/anxiety in both high-income 
and low-income countries and in different general phys-
ical healthcare settings, namely primary, secondary care 
and ED.
Several methods have been studied to try to improve 
the care of high-cost or high-use patients in the hope 
of reducing excessive or unnecessary healthcare use, 
but efforts to date have had mixed results.21 22 Evidence 
suggests that effectiveness and efficiency of care improves 
when interventions are targeted to those who are most 
likely to benefit.23 24 Specific interventions for treating 
depression and anxiety in people with comorbid physical 
health problems have shown promising results25 26 but 
have not been targeted at high-cost patients with comorbid 
depression/anxiety.
Improved recognition of the association of depres-
sion and anxiety with high healthcare use and costs will 
enable treatments that have already been developed for 
depression/anxiety in physical disease to be evaluated 
in this high need/high cost group. Although there has 
been a general call for better integration of physical and 
mental health services, the treatment and management of 
comorbid depression/anxiety in chronic physical disease 
remains poorly managed.27
Our aim is to estimate the prevalence of anxiety/depres-
sion in adults who are high users of healthcare or accrue 
high healthcare costs and where possible to estimate the 
magnitude of use associated with anxiety/depression. 
Segmentation analysis has been suggested as a method 
to identify homogeneous groups of patients with similar 
characteristics, needs and behaviours to personalise 
treatment and policy.28 We are specifically interested in 
depression and anxiety, as opposed to all mental health 
problems, as interventions have already been developed 
to treat depression/anxiety when associated with phys-
ical disease. Such interventions could be used to target a 
subgroup of high-use/high-cost patients with the poten-
tial to improve their health and reduce healthcare use. 
Other forms of mental illness require other treatment 
approaches.
Aims
This systematic review will aim to: (1) estimate the prev-
alence of anxiety and/or depression in patients who 
are high users of healthcare or accrue high healthcare 
costs and (2) determine the magnitude of healthcare 
use/cost associated with the presence of anxiety and/or 
depression.
METhOdS And dESIgn
Population
This review will include studies focusing on adults aged 
≥18 years, who are high users of healthcare services or 
accrue high healthcare costs and whose level of depres-
sion/anxiety have been evaluated through standardised 
questionnaires or clinical interviews. We include studies 
conducted in general rather than specialist physical 
health services, namely primary, secondary care and ED 
across all healthcare systems. We will not include studies 
with populations seen in the context of psychiatric or 
mental health services for a primary diagnosis of a psychi-
atric condition (ie, psychosis, schizophrenia) as the aim is 
to estimate the prevalence of anxiety/depression among 
high users of general physical healthcare services. We will 
not include specific medical specialties/illnesses asso-
ciated with more frequent or costly healthcare use due 
to the nature of the condition or specialty (eg, surgery, 
paediatrics, palliative care, obstetrics, transplant, neuro-
degenerative diseases, oral and maxillofacial, dentistry, 
nephrology, infectious diseases, virology and HIV/AIDS 
studies, physiotherapy and cosmetic surgery).
We have focused on general hospital, ED and primary 
care services to ensure the review is relevant to as wide 
a population as possible. There is great variability in the 
way costs, healthcare use and depression/anxiety have 
been recorded in the literature. To add studies on indi-
vidual disease conditions or specialities would consider-
ably inflate the variability within the population of this 
review.
For studies of high-cost patients, we will include studies 
that have defined high-cost patients as being in the top 
1st, 5th, 10th and 20th percentiles of the patient popu-
lation.20 For studies involving high use of healthcare, we 
will include studies that have either used similar percen-
tiles to describe high use (ie, 1st, 5th, 10th or 20th) or 
have used a recognised definition of high or frequent use 
for the particular healthcare services. For ED, we will use 
the definition of four or more attendances per annum.29 
For primary care, we will use the definition of 10 or more 
attendances per year30 or the top 10% of consulters.31
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The review will include studies reporting costs and 
healthcare use. However, resource use and costs are sensi-
tive to variability both within and between countries due 
to aspects such as local prices or aspects of service organ-
isation and delivery. This may limit the generalisability 
and transferability of estimates of cost and healthcare 
across settings. We will not attempt to combine costs or 
health use in the analyses across studies. The prevalence 
of depression or anxiety will be compared across studies. 
To determine the magnitude of healthcare use associated 
with depression/anxiety in high-use/high-cost patients, 
we will estimate the healthcare used by depressed and 
non-depressed individuals. If sufficient studies report 
similar effect measures (eg, odds ratio ORs, relative risk, 
incidence rate ratios) of the frequency of healthcare use 
in these patients,32 they will be combined in a meta-anal-
ysis, consistent with current recommendations.33–35 
Studies reporting different effect measures will not be 
combined, unless they can be transformed.34 35
Interventions
We will not include randomised controlled trials due to 
their selective nature. We will include cohort studies of 
naturalistic changes in health service delivery for example, 
implementation of a new integrated care pathway across 
a geographical region, where external validity is likely to 
be high.
Comparators
We will include studies where anxiety/depression is 
described in groups of patients considered ‘high/
frequent users’ and/or ‘high cost users’ versus non-high 
cost and non-high users of healthcare services. We will 
include studies where high healthcare use/costs are 
compared between patients with anxiety/depression 
versus study patients without anxiety/depression.
Outcomes
The primary outcome is the prevalence of anxiety/
depression in high/frequent and/or costly users of 
general healthcare services. The secondary outcome is 
the magnitude of healthcare use and costs associated with 
anxiety/depression. Studies including a diverse range 
of standardised assessments and metrics for anxiety/
depression will be eligible. We will extract and report the 
prevalence of anxiety/depression based on the type of 
assessments used. For standardised, validated, self-report 
measures, this will be in the form of caseness. For clinical 
interviews, this will be in the form of a clinical diagnosis. 
Studies will be excluded if they do not meet our criteria 
for the assessment of anxiety or depression. A review 
concerning general mental health disorders has already 
been undertaken by Wammes et al.20
Study designs
We will include retrospective and prospective cohort 
studies, case–control, nested case–control and cross-sec-
tional studies. We will exclude case studies, randomised 
controlled trials and qualitative studies.
Search strategy
We will screen the five databases that are most likely to 
include studies focusing on our outcomes of interest: 
Medline, PsychINFO, Embase, Cumulative Index to 
Nursing and Allied Health Literature, Prospective 
Register of Systematic Reviews, Cochrane Library, from 
inception to 1 April 2019. We will hand-search refer-
ence lists of relevant reviews/meta-analyses. For each 
database our search strategy has three parts (see search 
terms for Medline in online supplementary appendix 
1). Search terms within the first part will identify studies 
pertaining to general healthcare settings of interest. 
The second part will focus on terms related to high cost 
or high/frequent use of healthcare services. The final 
part will focus the search on studies evaluating anxiety/
depression. This strategy ensures we identify all studies 
(1) conducted across general healthcare settings such 
as primary, secondary care and ED; (2) which include 
measurements of healthcare use and/or costs (3) and 
assess anxiety/depression. We will not be able to include 
studies that do not quantify either healthcare use or costs 
and studies that do not quantify anxiety/depression. This 
strategy ensures we include cohort studies describing 
the characteristics of high-use and/or high-cost patients 
and case–control studies where (1) anxiety/depression 
is compared between high and low use and/or costs, as 
defined by the respective study or where (2) healthcare 
use/costs is compared between patients with high and 
low levels of anxiety/depression, as defined by the study.
The strategy was developed in collaboration with 
experts in these fields and experienced librarians at the 
universities of Birmingham and Manchester to ensure it 
yields appropriate studies. We will include studies in all 
languages; translations will be pursued either by coau-
thors or by international colleagues/students in the 
universities of Birmingham, Leeds and Manchester. The 
search will be restricted to studies with adults over the age 
of 18.
Eligibility screening
Eligible studies identified in all the databases will be 
organised using the EndNote reference management 
software. Duplicates will be identified and removed 
before screening titles and abstracts.
Study selection
Titles and abstracts will be screened independently by 
two reviewers. Remaining full-text articles will be further 
screened and evaluated for their eligibility using the 
adapted Hayden et al’s framework36 (see online supple-
mentary appendix 2). Any disagreement over eligi-
bility will be resolved through discussions with a third 
reviewer. The inclusion criteria checklist (table 1 and 
online supplementary appendix 2) ensures consistency 
in the review process and adherence to the Preferred 
Reporting Items for Systematic Reviews and Meta-Anal-
yses (PRISMA) guidelines37; we will provide a PRISMA 
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Table 1 Inclusion criteria checklist based on the PRISMA 
guidelines
Study 
designs
Cohort studies (retrospective and 
prospective).
Case–control and nested case–control 
studies.
Cross-sectional studies.
Participants Adult aged ≥18 years.
High user of healthcare.
Accrue high healthcare costs.
Assessment of anxiety/depression.
Comparators Non-high cost and non-high users of 
healthcare.
Frequent/high-cost users without depression/
anxiety.
Outcomes Prevalence of anxiety/depression in high 
users of healthcare and/or high-cost patients.
Magnitude of cost or use of healthcare 
associated with the presence of anxiety/
depression.
PRISMA, Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses.
flow-chart depicting the study selection and inclusion/
exclusion process.
Quality assessment
The quality of the included studies will first be ensured 
through the robustness of our database search and the 
careful title, abstract and full-text screening of relevant 
studies, carried out independently by two reviewers using 
the forms in online supplementary appendix 2. We will 
only include studies reporting on high or costly users 
of healthcare where anxiety/depression is also assessed. 
All full-text studies meeting the eligibility criteria will 
undergo a quality assessment carried out independently 
by two reviewers through an adapted Newcastle-Ot-
tawa Scale38 (NOS; see online supplementary appendix 
3). Assessment of study quality will include sampling 
method, sample size, adequacy of description of study 
population, attrition, method of outcome evaluation 
(eg, methods for recording costs/use; type of anxiety/
depression measurements, whether they are validated 
for the setting and so on), analytical method and consid-
eration of confounders/covariates. The adapted NOS 
quality assessment form will first be piloted on known 
papers to ascertain its feasibility. Opinion differences will 
be resolved by consensus or by involving a third reviewer. 
Risk of bias (including reporting bias) will be evaluated 
commensurate with recent recommendations for the 
narrative interpretation of variation in observational 
studies34 35 and the recommendations of the Cochrane 
Collaboration.39 40 Risk of bias will be reported in a cate-
gorical format, with ‘yes’ indicating high risk, ‘no’ low risk 
or ‘unclear’ for each predefined domain. We will describe 
the study quality and risk of bias for each study included 
in our review. For both low-quality and high-quality 
studies, we will provide a narrative description of defini-
tions and measurements of costs and healthcare use and 
prevalence of anxiety/depression used across healthcare 
settings, regions and patient populations. If a meta-anal-
ysis can be pursued, we will run a sensitivity analysis to 
explore if outcomes change when removing low-quality 
studies. Through sensitivity analyses, we will also specifi-
cally explore the effects of excluding studies which have 
used non-validated measures of depression/anxiety in 
medically ill populations.
data extraction
Following the selection of relevant full-text articles and 
quality assessment, two reviewers will independently 
extract relevant information in a data extraction form 
designed based on Hayden et al’s framework36 (see 
online supplementary appendix 2); it will be developed 
iteratively and first piloted on five known papers, by two 
reviewers, before performing the data extraction for all 
studies.
The data extraction form focuses on the study design, 
population, comparator and outcome. It will include: 
year and country of study, type of healthcare system, 
criteria used to define high use or high costs, method 
used to record depression/anxiety (self-report measure 
validated or non-validated, clinical interview), preva-
lence of depression and anxiety, healthcare use, costs and 
associated ranges, the methods used to evaluate these, 
healthcare settings (eg, primary, secondary or ED or 
total healthcare use/cost, if reported as general metrics), 
healthcare use and cost estimates for depressed/anxious 
patients compared with non-depressed/anxious patients 
and patient characteristics (eg, comorbidities, whether 
anxiety/depression is managed). We will also record the 
presence and source of bias, including funding, given its 
potential association with reporting bias.39 40
dATA AnAlySIS And SynThESIS
The primary outcome is the prevalence of anxiety and/
or depression in patients who are high and/or costly 
users of healthcare services. Prevalence rates with any 
dispersion metrics will be extracted or calculated from 
the data available. Where enough studies are available 
for quantitative summaries (minimum two studies41), we 
will offer weighted estimates of prevalence within relevant 
subgroups related to populations, comparators, study 
designs, measurement types and geographical regions. 
Pooled prevalence estimates with 95% CIs will be calcu-
lated using SPSS V.25 (IBM Corp); where possible and 
warranted, estimate transformations and quantitative 
summaries will be pursued using R.33
The secondary outcome is the magnitude of health-
care use orcost associated with the presence of anxiety/
depression. We are not attempting to pool or calculate 
costs or health use across studies. We will only be able 
to determine the magnitude of healthcare use associated 
with depression/anxiety in relation to studies that have 
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specifically calculated or estimated these. This will be 
studies where high healthcare use/costs are compared 
between patients with anxiety/depression versus patients 
without anxiety/depression. Outcome metrics (including 
ORs, relative risk, etc) and 95% CIs will be extracted from 
studies presenting the number of healthcare contacts (eg, 
ED attendances or GP contacts or number of hospital 
admissions) by subjects with and without depression.
We expect both the prevalence of depression/anxiety 
to be available from studies evaluating high-use/high-
cost populations alone or in studies comparing high-use/
high-cost patients to general patient populations or popu-
lations with low use/cost. Data analysis will result in quan-
titative and narrative summaries, as appropriate, based on 
current recommendations for the pooling of observational 
studies.34 35 Whereas there is some published guidance 
on the number of studies necessary to ensure the power 
of the effect size estimates when pooling interventional 
studies,32 42 there are no similar clear, agreed guidelines 
on the number of studies necessary for an appropriately 
powered meta-analysis of observational studies. We will 
offer a quantitative summary for any number of studies 
(2>) if combining their outcomes is clinically meaningful, 
if they report the same effect metrics or if transformations 
are possible.34 35 41 We will comment on these pooled 
results in light of clinical practice and research signif-
icance and potential statistical issues that may decrease 
the generalisability of the effect estimates (eg, high level 
of heterogeneity, potential sources of bias). For both 
outcomes, subgroups will be explored quantitatively and 
narratively, as appropriate and depending on the type of 
effect estimates available, based on potential differences 
related to: (1) country, (2) type of healthcare system, (3) 
medical settings (eg, primary, secondary care, ED, inpa-
tients, outpatients, etc) and (4) metrics used to evaluate 
health use/costs (eg, attendances, hospital admissions, 
etc). For instance, we expect to find studies that may only 
focus on frequent attendance at ED, primary care outpa-
tient visits, number of bed days in secondary care or more 
generic attendance metrics across either of these health-
care settings. We will account for such differences in 
reporting, but we are not planning to compare outcomes 
across settings, just to record and estimate the magnitude 
of use/cost in each of these contexts.
We will use random-effects models to describe the preva-
lence of depression/anxiety high-use or high-cost popula-
tions. This is because it is implausible that the underlying 
study-specific prevalence of depression (ie, the preva-
lence that would be observed were a study of infinite size) 
is the same for each study. Prevalence is likely to vary from 
study to study according to factors, both measured and 
unmeasured, that differ between them.43
We will use the inverse variance method of DerSimo-
nian and Laird to estimate between-study heterogeneity 
in underlying depression prevalence and the I2 measure 
with associated 95% CIs, which represents the proportion 
of total variance attributable to this heterogeneity.39 44 
The I2 measure gives the percentage of variability in the 
effect estimate that is due to heterogeneity rather than 
to chance. A rough guide to the interpretation of the I2 
measure suggests that I2 <40% indicates low to no prob-
lems with heterogeneity, 30% to 60% indicates moderate 
problems, 60% to 90% indicates significant problems, 
whereas an I2 of 75% or more suggests considerable prob-
lems.42 If I2 is less than 40%, we will consider the estimated 
effect to have a low degree of heterogeneity, but this will 
also be interpreted in light of the magnitude, direction 
of the effect and its 95% CI, sources of bias and clinical 
significance.35 39 41 42
Egger’s statistics with 95% CIs and associated funnel 
plot will depict potential publication or small sample bias 
related to our main outcome summaries and/or within 
subgroups.45 Egger’s test is based on the Galbraith plot 
which is a plot of study difference over standarderror 
against 1/standarderror. Egger suggests calculating the 
regression of study difference over standarderror on 
1/standarderror be undertaken to test the null hypoth-
esis that the intercept is equal to zero. If Egger’s test is 
significant (p<0.05), it means that the funnel plot is 
asymmetric and that smaller studies with smaller preci-
sion show larger effects sizes, suggesting bias. Sensitivity 
analyses will be pursued at minimum on high-quality/
low-quality studies on the use of unvalidated standardised 
questionnaires and use of structured clinical interviews. 
If enough studies are available, other factors that could 
influence our observed findings will be explored (eg, 
sample size). Tabular and narrative descriptions will be 
offered for the studies which cannot be pooled into quan-
titative summaries due to differing metrics.
Patient and public involvement statement
Patients and the public were not invited to contribute to 
the writing or editing of this systematic review protocol. 
The research question was informed by the lack of 
prior systematic reviews or meta-analyses exploring the 
outcomes of interest: prevalence of anxiety/depression 
in highly/costly healthcare users and the magnitude of 
healthcare use associated with anxiety/depression across 
adult populations in any general medical settings.
dISCuSSIOn
The purpose of this systematic review is to estimate the 
prevalence of anxiety/depression in people who are 
frequent, high-cost users of general healthcare services, 
and then, if possible, to estimate the level of healthcare use 
associated with the presence of anxiety/depression. While 
evidence is available suggesting that a small percentage of 
the population accrues a high percentage of healthcare/
costs, it is unclear to date to what extent the costs and use 
may be due to the presence of common mental health 
problems (depression/anxiety). By examining the infor-
mation available to date, we aim to describe the preva-
lence of anxiety/depression in people who are highly/
costly healthcare users and where possible the magnitude 
H
ospital M
edical Library. Protected by copyright.
 o
n
 Septem
ber 5, 2019 at Assistant Librarian St Jam
es`s
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-028295 on 4 September 2019. Downloaded from 
6 Jadhakhan F, et al. BMJ Open 2019;9:e028295. doi:10.1136/bmjopen-2018-028295
Open access 
of use or costs associated with these two common mental 
health problems.
Our review will build on the recent systematic review 
by Wammes and colleagues20 that described the char-
acteristics of high-cost patients and found that a high 
prevalence of high-cost patients had associated mental 
health disorders. This review will specifically focus on 
depression/anxiety and include both studies of cost and 
healthcare use. It will also provide information about the 
prevalence of depression/anxiety in different health-
care settings, including primary care and ED. There is 
a trade-off between diagnostic accuracy versus size of 
study. Our results will complement those of Wammes and 
colleagues20 and increase our understanding of the role 
of depression/anxiety in driving healthcare use and costs.
Strengths of this review are that it focuses on common 
mental health problems, includes both studies of health-
care cost and healthcare use and includes general health-
care settings, including primary, secondary care and 
ED. Additional strengths are the inclusion of studies 
published in any language and the independent study 
identification, selection and data extraction pursued by 
two independent reviewers.
Implications of results
The results of this systematic review will provide an 
estimate of the prevalence of common mental health 
disorders in high users of healthcare services, while also 
providing an estimate of the magnitude of use associated 
with depression/anxiety. It will enable treatments, such 
as the collaborative care model, that have already been 
developed for the treatment of depression/anxiety in the 
physically ill, to be evaluated in high-cost patients with 
comorbid depression/anxiety resulting in a more person-
alised approach to both treatment and policy.
Ethics and dissemination
As this systematic review will use data from existing studies 
no ethical approvals are warranted; the results will bepub-
lished in a peer-reviewed publication and presented at 
relevant academic meetings.
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